S1105 |
LY294002
|
LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis. |
-
Signal Transduct Target Ther, 2024, 9(1):109
-
Signal Transduct Target Ther, 2024, 9(1):109
-
Nat Commun, 2024, 15(1):2612
|
|
S2758 |
Wortmannin
|
Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity. |
-
Nat Commun, 2024, 15(1):451
-
Nat Commun, 2024, 15(1):4926
-
Phytomedicine, 2024, 132:155892
|
|
S2638 |
NU7441 (KU-57788)
|
NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage. |
-
Nat Cell Biol, 2024, 10.1038/s41556-024-01394-y
-
Nat Commun, 2024, 15(1):2089
-
Nucleic Acids Res, 2024, gkad1224
|
|
S1038 |
PI-103
|
PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. PI-103 induces apoptosis in murine T-cell Lymphoma. |
-
Cancers (Basel), 2024, 16(13)2447
-
bioRxiv, 2024, 2024.02.19.581073
-
J Transl Med, 2023, 21(1):89
|
|
S2871 |
T0070907
|
T0070907 is a potent inhibitor of PPARγ (peroxisome proliferator activator receptor γ ) that induces G2/M arrest and enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. It also acts as an antagonist of PPARγ that suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms. |
-
Nat Commun, 2024, 15(1):1429
-
Bone Res, 2024, 12(1):15
-
Biomolecules, 2024, 14(5)596
|
|
S2817 |
Torin 2
|
Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM in p53−/− MEFs cell line; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. Inhibition of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively. Torin 2 decreases cell viability and induces autophagy and apoptosis. |
-
Microorganisms, 2024, 12(2)296
-
Autophagy, 2023, 19(11):2912-2933
-
Autophagy, 2023, 19(11):2912-2933
|
|
S2893 |
NU7026
|
NU7026 (LY293646) is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. NU7026 enhances G2/M cell arrest and apoptosis. |
-
Nucleic Acids Res, 2024, gkae156
-
Stem Cell Res, 2024, 77:103424
-
bioRxiv, 2024, 2024.05.03.592391
|
|
S1205 |
PIK-75 HCl
|
PIK-75 HCl is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM in cell-free assays. |
-
Cancers (Basel), 2024, 16(2)370
-
Cancer Res, 2023, 83(3):456-470
-
Mol Ther Nucleic Acids, 2023, 31:309-323
|
|
S8843 |
AZD7648
|
AZD7648 is a potent inhibitor of DNA-PK with an IC50 of 0.6 nM in biochemical assay and more than 100-fold selective against 396 other kinases. |
-
Nat Commun, 2024, 15(1):2625
-
Mol Ther, 2024, S1525-0016(24)00399-X
-
Cells, 2024, 13(4)304
|
|
S8045 |
KU-0060648
|
KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM. |
-
Breast Cancer Res, 2022, 24(1):41
-
Biomedicines, 2021, 9(5)579
-
Chembiochem, 2021, 22(12):2177-2181
|
|
S7891 |
CC-115
|
CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR) with IC50 values of 0.013 μM and 0.021 μM, respectively. It has potential antineoplastic activity. |
-
Nat Commun, 2024, 15(1):2625
-
Cells, 2024, 13(4)304
-
Mol Ther Nucleic Acids, 2023, 31:309-323
|
|
S8586 |
Nedisertib (M3814)
|
Nedisertib (M3814, Peposertib, MSC2490484A) is an orally bioavailable, highly potent and selective inhibitor of DNA activated protein kinase (DNA-PK) with IC50 of < 3 nM. |
-
Cell Discov, 2024, 10(1):78
-
Nat Commun, 2024, 15(1):2625
-
Nucleic Acids Res, 2024, gkae316
|
|
S8322 |
Samotolisib (LY3023414)
|
Samotolisib (LY3023414, GTPL8918) is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
-
Exp Ther Med, 2023, 25(1):19
-
Explor Target Antitumor Ther, 2023, 4(1):139-156
-
Cold Spring Harb Mol Case Stud, 2022, 8(1)a006140
|
|
S2622 |
PP121
|
PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM. |
-
Life Sci Alliance, 2021, 4(2)e202000882
-
PLoS One, 2016, 11(10):e0164895
-
PLoS One, 2016, 11(10):e0164895
|
|
S8589 |
SF2523
|
SF2523 is a highly selective and potent inhibitor of PI3K with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively. |
-
Mol Ther Nucleic Acids, 2023, 31:309-323
-
Cell Biol Int, 2022, 10.1002/cbin.11833
-
Oncotarget, 2017, 8(58):98471-98481
|
|
S8379 |
YU238259
|
YU238259 is a novel inhibitor of homology-dependent DNA repair(HDR), but does not inhibit non-homologous end-joining (NHEJ), in cell-based GFP reporter assays. |
-
Theranostics, 2023, 13(3):1130-1149
-
Int J Mol Sci, 2020, 21(16)E5821
|
|
S8427 |
LTURM34
|
LTURM34 is a specific DNA-PK inhibitor, 170-fold more selective for DNA-PK activity compared to PI3K activity, with IC50 value of 0.034 μM. |
-
Front Oncol, 2023, 13:1287444
-
Int J Mol Sci, 2021, 22(19)10512
|
|
S6506 |
Compound 401
|
Compound 401 is a synthetic inhibitor of DNA-PK(IC50=0.28 μM) and mTOR (IC50=5.3 μM). It has no inhibition on p110α/p85α PI3K (>100 μM) and blocks the phosphorylation of S6 kinase 1 Thr389 and Akt Ser473 in COS7 cells. |
|
|
S1105 |
LY294002
|
LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis. |
- Signal Transduct Target Ther, 2024, 9(1):109
- Signal Transduct Target Ther, 2024, 9(1):109
- Nat Commun, 2024, 15(1):2612
|
|
S2758 |
Wortmannin
|
Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity. |
- Nat Commun, 2024, 15(1):451
- Nat Commun, 2024, 15(1):4926
- Phytomedicine, 2024, 132:155892
|
|
S2638 |
NU7441 (KU-57788)
|
NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage. |
- Nat Cell Biol, 2024, 10.1038/s41556-024-01394-y
- Nat Commun, 2024, 15(1):2089
- Nucleic Acids Res, 2024, gkad1224
|
|
S1038 |
PI-103
|
PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. PI-103 induces apoptosis in murine T-cell Lymphoma. |
- Cancers (Basel), 2024, 16(13)2447
- bioRxiv, 2024, 2024.02.19.581073
- J Transl Med, 2023, 21(1):89
|
|
S2871 |
T0070907
|
T0070907 is a potent inhibitor of PPARγ (peroxisome proliferator activator receptor γ ) that induces G2/M arrest and enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. It also acts as an antagonist of PPARγ that suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms. |
- Nat Commun, 2024, 15(1):1429
- Bone Res, 2024, 12(1):15
- Biomolecules, 2024, 14(5)596
|
|
S2817 |
Torin 2
|
Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM in p53−/− MEFs cell line; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. Inhibition of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively. Torin 2 decreases cell viability and induces autophagy and apoptosis. |
- Microorganisms, 2024, 12(2)296
- Autophagy, 2023, 19(11):2912-2933
- Autophagy, 2023, 19(11):2912-2933
|
|
S2893 |
NU7026
|
NU7026 (LY293646) is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. NU7026 enhances G2/M cell arrest and apoptosis. |
- Nucleic Acids Res, 2024, gkae156
- Stem Cell Res, 2024, 77:103424
- bioRxiv, 2024, 2024.05.03.592391
|
|
S1205 |
PIK-75 HCl
|
PIK-75 HCl is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM in cell-free assays. |
- Cancers (Basel), 2024, 16(2)370
- Cancer Res, 2023, 83(3):456-470
- Mol Ther Nucleic Acids, 2023, 31:309-323
|
|
S8843 |
AZD7648
|
AZD7648 is a potent inhibitor of DNA-PK with an IC50 of 0.6 nM in biochemical assay and more than 100-fold selective against 396 other kinases. |
- Nat Commun, 2024, 15(1):2625
- Mol Ther, 2024, S1525-0016(24)00399-X
- Cells, 2024, 13(4)304
|
|
S8045 |
KU-0060648
|
KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM. |
- Breast Cancer Res, 2022, 24(1):41
- Biomedicines, 2021, 9(5)579
- Chembiochem, 2021, 22(12):2177-2181
|
|
S7891 |
CC-115
|
CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR) with IC50 values of 0.013 μM and 0.021 μM, respectively. It has potential antineoplastic activity. |
- Nat Commun, 2024, 15(1):2625
- Cells, 2024, 13(4)304
- Mol Ther Nucleic Acids, 2023, 31:309-323
|
|
S8586 |
Nedisertib (M3814)
|
Nedisertib (M3814, Peposertib, MSC2490484A) is an orally bioavailable, highly potent and selective inhibitor of DNA activated protein kinase (DNA-PK) with IC50 of < 3 nM. |
- Cell Discov, 2024, 10(1):78
- Nat Commun, 2024, 15(1):2625
- Nucleic Acids Res, 2024, gkae316
|
|
S8322 |
Samotolisib (LY3023414)
|
Samotolisib (LY3023414, GTPL8918) is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
- Exp Ther Med, 2023, 25(1):19
- Explor Target Antitumor Ther, 2023, 4(1):139-156
- Cold Spring Harb Mol Case Stud, 2022, 8(1)a006140
|
|
S2622 |
PP121
|
PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM. |
- Life Sci Alliance, 2021, 4(2)e202000882
- PLoS One, 2016, 11(10):e0164895
- PLoS One, 2016, 11(10):e0164895
|
|
S8589 |
SF2523
|
SF2523 is a highly selective and potent inhibitor of PI3K with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively. |
- Mol Ther Nucleic Acids, 2023, 31:309-323
- Cell Biol Int, 2022, 10.1002/cbin.11833
- Oncotarget, 2017, 8(58):98471-98481
|
|
S8379 |
YU238259
|
YU238259 is a novel inhibitor of homology-dependent DNA repair(HDR), but does not inhibit non-homologous end-joining (NHEJ), in cell-based GFP reporter assays. |
- Theranostics, 2023, 13(3):1130-1149
- Int J Mol Sci, 2020, 21(16)E5821
|
|
S8427 |
LTURM34
|
LTURM34 is a specific DNA-PK inhibitor, 170-fold more selective for DNA-PK activity compared to PI3K activity, with IC50 value of 0.034 μM. |
- Front Oncol, 2023, 13:1287444
- Int J Mol Sci, 2021, 22(19)10512
|
|
S6506 |
Compound 401
|
Compound 401 is a synthetic inhibitor of DNA-PK(IC50=0.28 μM) and mTOR (IC50=5.3 μM). It has no inhibition on p110α/p85α PI3K (>100 μM) and blocks the phosphorylation of S6 kinase 1 Thr389 and Akt Ser473 in COS7 cells. |
|
|